University Of California Davis

The UC Davis CTSC holds its 16th Annual Scholar Symposium This week, the UC Davis Clinical and Translational Science Center (CTSC) celebrated the graduation of its newest cohort of scholars who conduct innovative applied health research. During its 16th annual CTSC Scholar Symposium, 43 researchers presented their work to mentors and colleagues. The event commenced with a welcome from Frederick J

Kate Marusina, director of the CTSC Clinical Trials Office, oversees a team that provides support for clinical trials at UC Davis. UC Davis conducts more than 2,000 research studies at any given time, including basic science, translational, and clinical trial research — all with the goal of bringing new, effective, and safe treatments to patients more quickly. In this brief interview conducted by

A team of UC Davis Health scientists is working to identify factors that could predict brachial plexus birth injury (BPBI), the leading cause of infants’ upper extremity paralysis. They are developing a predictive risk model of maternal and hospital factors associated with the condition. Their work seeks to inform better prevention strategies and shift the current standard practices for this

Oanh Meyer, assistant professor of neurology at UC Davis School of Medicine, has a long history of working with the Asian American communities in Sacramento on mental health and Alzheimer’s disease issues. With her team in the Diversity and Disparities Lab, she engages in community outreach efforts to better understand and fight health disparities. In her line of work, she has seen a great need in

The University of California, Davis and InVixa Inc., a biopharmaceutical startup, have executed a licensing agreement for a novel method using inhaled statins to treat the severe respiratory disease known as COVID-19. The license, negotiated by the InnovationAccess team within the UC Davis Office of Research, provides exclusive access for InVixa to commercialize the technology developed at the

The CTSC Clinical Research Center (CCRC) at UC Davis Health received the Patient Safety Innovation Award for supporting the pioneering research into a #COVID-19 #pfizer #vaccine. Under the leadership of Daniel Nishijima, M.D., M.A.S., and Christopher Kain, RN, M.S.N., the team serves as the clinical component of the UC Davis Clinical and Translational Science Center (CTSC), funded by an NIH grant

Healthy Davis Together is a joint project between the City of Davis and UC Davis with a goal to prevent the spread of COVID-19 and facilitate a coordinated and gradual return to regular city activities and reintegration of UC Davis students back into the Davis community. The program was set up and runs with the support of the UC Davis Clinical and Translational Science Center (CTSC). The rapid

UC Davis CTSC KL2 Scholar’s work included in National Endowment for the Arts report Ian Koebner’s Art Rx Program was recently profiled in a published report from the National Endowment for the Arts. The report, Arts Strategies for Addressing the Opioid Crisis: Examining the Evidence, centers on arts integration in pain management and the prevention and treatment of substance use disorder

UC Davis CTSC KL2 Scholar’s work included in National Endowment for the Arts report Ian Koebner’s Art Rx Program was recently profiled in a published report from the National Endowment for the Arts. The report, Arts Strategies for Addressing the Opioid Crisis: Examining the Evidence, centers on arts integration in pain management and the prevention and treatment of substance use disorder

Jennifer Rosenthal, assistant professor of clinical pediatrics, will begin a four-year K23 Mentored Patient-Oriented Research Career Development Award funded by the National Institute of Child Health and Human Development (NICHD) to study pediatric interfacility transfers. Pediatric interfacility transfers are frequent but poorly studied events. Dr. Rosenthal’s project, “Telemedicine Consultations

Stephanie Crossen, a pediatric endocrinologist and assistant professor of clinical pediatrics at UC Davis Health, will begin a four-year K23 training award funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Dr. Crossen will study several ways to leverage telehealth and connected health technology to improve care delivery and outcomes for children and

Four UC Davis research centers will share a $3.7 million grant to offer free COVID-19 testing for agricultural workers in the Central Valley, where the coronavirus pandemic has reached alarming levels, the National Institutes of Health (NIH) announced Wednesday. The funding for the UC Davis Environmental Health Sciences Center, Clinical and Translational Science Center (CTSC), Center for Reducing

Sergio Aguilar-Gaxiola, director of the UC Davis Center for Reducing Health Disparities, has received a prestigious award from the Mexican government for his work in advocating for the rights of Mexican nationals in the United States. The recognition – known as the Ohtli Award – is the highest honor granted by the Mexican government to individuals who have dedicated their lives to improving the

Children with autism born to mothers who had immune conditions during their pregnancy are more likely to have behavioral and emotional problems, a UC Davis Health study has found. The study examined maternal immune history as a predictor of symptoms in children with autism. “We tested the ability of maternal immune history to predict ASD symptoms and the possible role that the sex of the offspring

Patients at UC Davis Health today became the first in Sacramento to receive a vaccine candidate for COVID-19, which is part of a major clinical trial involving 30,000 participants worldwide. The six people who received the injection are part of a late-stage study that will enroll about 200 participants through UC Davis Health’s clinical trials program. “I’m excited about being able to be afforded

Drawing on electronic health records from across its academic health system, University of California Health has developed a unified, secure data set for use in COVID-19 research. The HIPAA Limited Data Set consisting of clinical information with more than 460 million data points is accessible to researchers across the entire UC system, enabling them to rapidly compare treatment options from

Drawing on electronic health records from across its academic health system, University of California Health has developed a unified, secure data set for use in COVID-19 research. The HIPAA Limited Data Set consisting of clinical information with more than 460 million data points is accessible to researchers across the entire UC system, enabling them to rapidly compare treatment options from

COVID-19 research and clinical trials throughout UC Davis have a quiet and crucial backbone that is hard to describe – even for the directors of this center providing the support. The Clinical and Translational Science Center (CTSC) is one of the unsung heroes of UC Davis’s COVID-19 research while also serving as protector of ongoing clinical trials during the pandemic. “We’re the infrastructure

As more health care providers adapt to telehealth to care for patients during the COVID-19 pandemic, some are finding occasional challenges with the experience when it’s new to them. Now, some help is available in a new set of how-to videos for health care providers from UC Davis pediatric endocrinologist Stephanie Crossen. Crossen shares her expertise alongside Jennifer Raymond, pediatric

Diana Miglioretti, dean’s professor and division chief of biostatistics in the department of Public Health Sciences, has won the prestigious Distinguished Investigator Award from the Association of Clinical and Translational Science (ACTS). Dr. Diana Miglioretti recognized for her research on breast cancer screening. The UC Davis School of Medicine nominated Miglioretti for the Distinguished

Marcus Deloney, a trainee in the UC Davis TL1 training program, was selected at one of the six presenters at the recent Association for Clinical and Translational Science (ACTS) virtual meeting. With over 500 abstracts submitted, selection for presentation represents the top 1%. His research focuses on the use of biologically derived therapeutics to prevent the progression of osteoarthritis. These

Introduction: Informed consent for research biospecimen donations is traditionally obtained through a face-to-face interaction with research staff and by signing an Institutional Review Board (IRB)-approved printed form. Electronic signatures (eSign) are routinely used in the electronic medical record (EMR) for the consenting of clinical services after patients review printed documentation. Our

UC Davis Health is honored to be part of Gov. Gavin Newsom’s COVID-19 Testing Task Force, a public-private collaboration to more quickly increase coronavirus testing capacity. Nam Tran, associate clinical professor of pathology and laboratory medicine is senior director of clinical pathology and oversees COVID-19 testing at UC Davis. “UC Davis is pleased to partner with Gov. Newsom on this

Expressive language sampling addresses urgent need in fragile X syndrome research and therapy A multi-university team of researchers found that expressive language sampling (ELS) can be useful in measuring outcomes in clinical trials targeting fragile X syndrome (FXS). According to their study, ELS, a set of procedures for collecting and analyzing spoken language in natural verbal interactions

UC Davis Health study a “big first step” in standardizing assessments Researchers at the UC Davis MIND Institute have updated and validated a series of tests delivered on an iPad to accurately assess cognitive processing in people with intellectual disability. The validation opens new opportunities for more rigorous and sensitive studies in this population, historically difficult to evaluate

The UC Davis CTSC Clinical Research Center is supporting two clinical trials underway for hospitalized patients with severe COVID-19, the disease caused by the novel coronavirus, SARS-CoV-2. The studies are evaluating the safety and effectiveness of two drugs — the investigational antiviral remdesivir, and sarilumab, a drug that blocks the body’s acute inflammatory response. “We have a critical